Osteoarthritis

Knee osteoarthritis is the one indication frankincense has been tested on repeatedly — eight or more randomised controlled trials plus several meta-analyses, showing clinically meaningful improvement in VAS pain and WOMAC function scores. The foundational study was a randomised, double-blind, placebo-controlled crossover trial that reduced knee pain and swelling and improved walking distance ^{2Reference 2Kimmatkar et al. · 2003RCTEfficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee — randomised, double-blind, placebo-controlled trialView study →}; larger placebo-controlled trials of the standardised extracts 5-Loxin and Aflapin followed ^{3,4Reference 3Sengupta et al. · 2008RCTA double-blind, randomized, placebo-controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee — randomised controlled trialView study →Reference 4Vishal et al. · 2011RCTA double-blind, randomized, placebo-controlled clinical study evaluating the early efficacy of Aflapin in subjects with osteoarthritis of knee — randomised controlled trialView study →}.

The mechanism is well characterised: AKBA is a direct, non-redox, non-competitive inhibitor of 5-lipoxygenase, blocking leukotriene synthesis — a different target from the COX pathway that NSAIDs act on.

Trial quality is uniformly low, most studies are industry-linked to the proprietary extracts they test, and a 2024 meta-analysis was null once heterogeneity was accounted for. Trials use extracts standardised to 30% AKBA at 100–250 mg/day — crude resin is not equivalent, since AKBA is under 1% of raw frankincense.

Topical comfrey has the largest effect size of any osteoarthritis herb. A double-blind, placebo-controlled RCT (n=220, comfrey root ointment 6 g/day for three weeks) found VAS pain fell 54.7% with comfrey versus 10.7% with placebo — a between-group difference of about 44% — with WOMAC improving in parallel ^{5Reference 5Grube et al. · 2007RCTEfficacy of a comfrey root extract ointment in painful osteoarthritis of the knee — double-blind, randomised, placebo-controlled trialView study →}. Two further randomised placebo-controlled trials tested comfrey-plus-tannic-acid combination products in knee OA ^{6,7Reference 6Laslett et al. · 2012RCTLaslett, L. L., et al. (2012). 4Jointz (comfrey extract plus tannic acid) reduces knee pain over 12 weeks in clinical knee osteoarthritis — randomised, placebo-controlled trial. Osteoarthritis and Cartilage. https://pubmed.ncbi.nlm.nih.gov/22863612/View study →Reference 7Smith et al. · 2011RCTComfrey root extract and tannic acid creams in osteoarthritis of the knee — randomised, placebo-controlled, double-blind trialView study →}. Comfrey is unusual among topical folk remedies in having at least seven randomised trials across sprains, back pain and knee OA.

Comfrey is for external use. Its pyrrolizidine alkaloids are hepatotoxic when absorbed in quantity, and the serious cases on record — veno-occlusive disease — follow oral use of PA-rich material ^{8,9Reference 8Mei et al. · 2010ReviewMetabolism, genotoxicity, and carcinogenicity of comfrey — reviewView study →Reference 9Yeong et al. · 1990Case reportHepatic veno-occlusive disease associated with comfrey ingestion — case reportView study →}. Applied to intact skin, which is what every comfrey trial tested and what modern PA-reduced ointments are made for, it has an unremarkable safety record.

Cayenne’s active constituent, capsaicin, has crossed fully into mainstream pharmacology. A 2024 systematic review and meta-analysis concluded that topical capsaicin reduces osteoarthritis pain versus placebo, with a modest effect size ^{10,11Reference 10Tshering et al. · 2024Meta-analysisEfficacy and safety of topical capsaicin in the treatment of osteoarthritis pain — systematic review and meta-analysisView study →Reference 11Laslett et al. · 2014ReviewCapsaicin for osteoarthritis pain — reviewView study →}.

The mechanism is distinctive: capsaicin is a TRPV1 agonist that, with repeated application, defunctionalises nociceptors and causes epidermal nerve-fibre retraction — it depletes the pain signal rather than blocking inflammation. Standard preparations are 0.025–0.075% creams applied three to four times daily for several weeks.

Blinding is a problem in capsaicin trials, since it produces an unmistakable burning sensation that makes placebo control difficult. Expect a burning sensation for the first several applications — it fades with continued use, and is the mechanism rather than a side effect.

Devil’s claw is the best-evidenced Western herb for osteoarthritis taken orally, and unusually for a traditional botanical its literature includes randomised placebo-controlled trials and a Cochrane systematic review ^{12,13Reference 12Gagnier et al. · 2004Systematic reviewHarpagophytum procumbens for osteoarthritis and low back pain — systematic reviewView study →Reference 13Oltean et al. · 2014Meta-analysisHerbal medicine for low-back pain — Cochrane systematic review and meta-analysisView study →}. A multicentre double-blind RCT (n=122, four months) compared cryoground powdered root (2,610 mg/day, ~60 mg harpagoside) against the slow-acting drug diacerhein, and pain and Lequesne functional scores improved equally in both arms ^{14Reference 14Chantre et al. · 2000RCTEfficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis — double-blind, randomised, multicentre trialView study →}. Equivalence to an active comparator without a placebo arm is weaker evidence than superiority over placebo.

Preparations are heterogeneous, trials run to a maximum of four months, and the one dedicated osteoarthritis RCT registered on ClinicalTrials.gov was terminated for loss of funding. Doses used are standardised to ≥50–60 mg harpagoside/day.

Ginger is one of the most heavily trialled herbs in the world, with over a hundred randomised trials indexed across all indications. For osteoarthritis specifically, a meta-analysis of randomised placebo-controlled trials found ginger efficacious ^{15Reference 15Bartels et al. · 2015Meta-analysisEfficacy and safety of ginger in osteoarthritis patients — meta-analysis of randomised placebo-controlled trialsView study →}. The mechanism is coherent — gingerols and shogaols inhibit both COX and LOX pathways, giving dual anti-inflammatory action.

Ginger roughly doubled treatment discontinuation versus placebo in osteoarthritis trials, driven by gastrointestinal effects — heartburn, reflux and belching. An effective treatment that people stop taking is a limited treatment, and the effect size is modest.

Osteoarthritis is arnica’s strongest human indication, and the evidence is for the topical gel, the form the herb is actually used in. A randomised, double-blind trial in 204 patients with radiologically confirmed hand osteoarthritis found an arnica tincture gel not inferior to 5% ibuprofen gel for pain and hand function over 21 days ^{16Reference 16Widrig et al. · 2007RCTChoosing between NSAID and arnica for topical treatment of hand osteoarthritis — randomised, double-blind studyView study →}, and an open multicentre trial reported WOMAC improvement in knee OA ^{17Reference 17Knuesel et al. · 2002Clinical trialArnica montana gel in osteoarthritis of the knee — open, multicentre clinical trialView study →}. The mechanism is defined: the sesquiterpene lactone helenalin inhibits NF-κB by directly targeting p65 ^{18Reference 18Lyss et al. · 1998In vitroThe anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65 — in vitroView study →}. Neither trial had a placebo arm, which is the main limitation.

Herbal arnica is not homeopathic arnica: the much larger post-surgical and bruising literature tests ultra-dilutions and is a separate, largely null body of evidence ^{19Reference 19Ernst et al. · 1998Systematic reviewEfficacy of homeopathic arnica — systematic review of placebo-controlled clinical trialsView study →}. Like comfrey, arnica is a topical: the trials, the tradition and the sensible use are all external.

Willow is the bark that gave us aspirin. Its salicin is metabolised to salicylic acid, giving a mechanistically obvious anti-inflammatory and analgesic action — this is the original NSAID, and the Cochrane review of herbal medicine for low back pain found willow bark among the better-supported options ^{13Reference 13Oltean et al. · 2014Meta-analysisHerbal medicine for low-back pain — Cochrane systematic review and meta-analysisView study →}. Osteoarthritis-specific trial evidence is thinner than the back-pain evidence, and salicin content varies widely between preparations.

The salicylate cautions carry across — salicylate allergy, anticoagulants, and the Reye’s-syndrome rule in children with viral illness — though willow bark is a far gentler proposition than aspirin: the salicin is released slowly by gut bacteria, and the bark’s tannins and flavonoids make it notably easier on the stomach than the isolated drug it inspired.

Meadowsweet is the other classical salicylate herb, and the plant that gave aspirin its name, from its old genus Spiraea. It carries salicin, salicylaldehyde and methyl salicylate, which the body converts to salicylic acid ^{20Reference 20Lozienė · 2023Variations in yield, essential oil and salicylates of Filipendula ulmaria inflorescences at different blooming stages — analytical studyView study →}, and it has been used for rheumatic and joint pain across European herbal practice for centuries. No controlled trial exists for osteoarthritis. The chemistry is real and the tradition is long, but no trial has carried the constituent through to a clinical effect. It has the same gentle-salicylate profile as willow.

Cannabis is widely used for chronic joint pain, and the subject of a large and rapidly moving literature on chronic pain in general — but there is no osteoarthritis-specific trial evidence for it, and pain-in-general findings do not transfer cleanly to a specific joint disease. Legal status varies enormously by jurisdiction.

A product combining Uncaria guianensis (cat’s claw) with maca has been reported to improve pain and stiffness in osteoarthritis — but the trial tested the combination, and cat’s claw is the ingredient with the independent anti-inflammatory evidence. Nothing isolates a maca effect. Maca’s supported directions are energy, mood and sexual function, not joints.